Condition: Glaucoma, Open-Angle · Ocular Hypertension · Sponsor: Amneal Pharmaceuticals, LLC
This is a randomized, double-blind, two-treatment, single-period, parallel design, multiple dose at multiple clinical trial sites designed to demonstrate bioequivalence with clinical endpoint in subjects with chronic open-angle glaucoma or ocular hypertension in both eyes. Test Product - Bimatoprost ophthalmic solution, 0.01% of Amneal EU, Limited Reference Product - LUMIGAN® (bimatoprost ophthalmic solution) 0.01% of Allergan, Inc.
This description comes directly from the study's public registry record.
Ilesh Changela, MBBS; MD · +91-79-67778300 · ilesh@amnealindia.com
Always discuss trial participation with your own doctor first.
| Eye Research Foundation Inc. | Newport Beach, California, United States | Recruiting |
| North Bay Eye Associates, Inc. | Petaluma, California, United States | Recruiting |
| Volusia Eye Associates | New Smyrna Beach, Florida, United States | Recruiting |
| Clayton Eye Clinical Research, LLC | Morrow, Georgia, United States | Recruiting |
| Coastal Research Associates, LLC | Roswell, Georgia, United States | Recruiting |
| Toyos Clinic | Nashville, Tennessee, United States | Recruiting |
| Keystone Research | Austin, Texas, United States | Not Yet Recruiting |
| Houston Eye Associates, North Loop | Houston, Texas, United States | Recruiting |
| Cheyenne Eye Clinic & Surgery Center | Cheyenne, Wyoming, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05401357